Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALETTE sepsis adaptive platform trial
2025-521371-31-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2026
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of interferon gamma-1b, octaplas lg, filgrastim, anakinra, hydrocortisone and 5 more in sepsis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: 28-day all-cause mortality and Days alive without life-supportive therapies at day 28. Planned start Jul 2026; status: authorised.
02
Drugs
interferon gamma-1boctaplas lgfilgrastimanakinrahydrocortisone
03
Conditions
sepsis
Beyond the preview
Go deeper on 2025-521371-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521371-31-00.